Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Open Access
- 3 February 2022
- journal article
- correction
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1